King's College London Study Reveals Nitazenes Deaths Underreported by a Third in UK

The Rise of Nitazenes: A New Threat in the UK's Opioid Landscape

Nitazenes, formally known as 2-benzylbenzimidazole (BBI) analogs, represent a class of highly potent synthetic opioids that have infiltrated the UK's illicit drug market over the past seven years. Originally developed in the 1950s as potential analgesics for human use, their extreme potency—up to 500 times stronger than heroin—led to the abandonment of further pharmaceutical development due to unacceptable risks of overdose and addiction. These lab-made compounds are inexpensive to produce and can be mixed into common street drugs like heroin or cocaine, often without users' knowledge, amplifying the danger for individuals seeking relief from pain or euphoria.

The emergence of nitazenes coincides with a broader surge in UK drug-related deaths, which exceeded 17,000 annually when combining drugs and alcohol. Official figures from the National Crime Agency (NCA) indicate 333 fatalities linked to nitazenes across the UK in 2024 alone, a stark rise from earlier years when these substances were barely detected. In Scotland, over 100 deaths have been attributed to them, signaling a potential public health emergency akin to the fentanyl crisis in North America, though on a smaller scale so far.

This influx has prompted urgent warnings from UK health authorities, including public health alerts emphasizing the unpredictability of street supplies contaminated with these invisible killers. For researchers and policymakers in the United Kingdom, understanding nitazenes' spread is crucial, particularly through data-driven insights from leading academic institutions like King's College London (KCL).

King's College London Publishes Landmark Study on Underreported Nitazene Fatalities

In a pivotal publication dated February 8, 2026, in the journal Clinical Toxicology, researchers led by Dr. Caroline Copeland from King's College London's Faculty of Life Sciences & Medicine revealed that deaths involving nitazenes may be underreported by as much as a third nationwide. Dr. Copeland, a Senior Lecturer in Pharmacology & Toxicology and Director of the National Programme on Substance Use Mortality (NPSUM), spearheaded a multidisciplinary team including collaborators from University College London (UCL), University of Bristol, London School of Hygiene & Tropical Medicine (LSHTM), University of Glasgow, and international partners.

The study addresses a critical gap in official statistics, primarily sourced from the Office for National Statistics (ONS), which relies on death certificates often lacking detailed toxicology. NPSUM, hosted at KCL, supplements this by analyzing comprehensive coroners' reports, providing a more nuanced view of substance-specific mortality.

This research builds on KCL's prior work, such as a 2025 analysis showing opioid-related deaths from 2011-2022 were 55% higher than ONS figures—39,232 versus 25,364—due to polydrug complexities and reporting lags. Such university-led initiatives underscore the vital role of higher education in tackling national health crises through rigorous, evidence-based investigation.

Unpacking the Science: How Nitazenes Evade Detection Postmortem

The core revelation of the KCL study lies in nitazenes' chemical instability in postmortem blood samples. Toxicology tests, which can take up to a month to process, often fail to detect these opioids because they degrade rapidly under real-world handling conditions. In controlled experiments using anesthetized rat models at UCL—conducted ethically under UK Home Office guidelines—researchers found only 14% of the administered nitazene remained detectable after simulating standard pathology procedures.

Step-by-step, the degradation process unfolds as follows: upon death, blood samples are collected and stored, often at room temperature initially before refrigeration. Nitazenes break down into metabolites that standard tests do not target, leading to false negatives. Modeling this against NPSUM data from Birmingham in 2023 revealed a 33% excess in drug deaths, plausibly explained by these missed detections.

This forensic challenge mirrors broader issues in drug mortality surveillance, where polydrug use (e.g., nitazenes mixed with benzodiazepines) complicates attribution. KCL's Addiction Sciences department, one of Europe's most prolific in the field, is at the forefront of refining detection methods to bridge these gaps.

Comparative Data: ONS vs. NPSUM and the Scale of Underreporting

ONS data provides total drug poisoning figures but undercounts specific substances like nitazenes due to reliance on incomplete death registrations. NPSUM's detailed triangulation—incorporating postmortems and toxicology—paints a grimmer picture. For instance, while NCA logged 333 nitazene-linked deaths in 2024, the study suggests the true toll could exceed 400 when accounting for degradation.

• ONS opioid attribution: ~47% of England/Wales drug poisonings in 2023.
• NPSUM adjustment: Up to 55% higher for opioids historically.
• Birmingham 2023: 33% excess deaths modeled to nitazenes.
• UK total drug/alcohol deaths: Over 17,000/year.

These discrepancies highlight why academic programs like NPSUM are indispensable for informing policy. Aspiring researchers can explore opportunities in this vital area via platforms like AcademicJobs.com/research-jobs, where positions in toxicology and public health abound.

Voices from the Frontline: Dr. Copeland and Stakeholder Perspectives

Dr. Caroline Copeland emphasized the human cost: “If nitazenes are degrading in post-mortem blood samples, then we are almost certainly undercounting the true number of deaths... Behind this undercount are people dying suddenly from extremely potent opioids, families left without answers.” Mike Trace of the Forward Trust echoed calls for bolder interventions like widespread drug testing.

Government officials note efforts such as Border Force's nitazene-detecting dogs—the world's first—and expanded naloxone distribution, an opioid reversal agent. Yet experts argue for enhanced funding to university research hubs to accelerate breakdown product identification and testing protocols.

In the UK's higher education sector, departments like KCL's National Addiction Centre foster careers blending clinical practice and research. Professionals interested in lecturer roles or postdocs can find tailored advice at AcademicJobs.com/higher-ed-career-advice.

Public Health Ramifications: From Policy to Prevention

Underreported nitazene deaths distort harm reduction strategies, potentially underfunding services for only two-thirds of the crisis. Regions like Birmingham and Scotland bear early brunt, with polydrug contamination heightening risks for vulnerable populations, including those in recovery or homeless communities.

Solutions include:

• Improved toxicology targeting nitazene metabolites.
• Drug checking services at festivals and services.
• Expanded take-home naloxone pilots, like Scotland's.
• Investment in university-led surveillance like NPSUM.

A Guardian analysis underscores the urgency, warning against complacency to avert a US-style epidemic where fentanyl drove 88% of opioid overdoses.

The Pivotal Role of UK Universities in Combating Synthetic Opioids

King's College London exemplifies how higher education drives solutions. Home to the Addiction Sciences Building and NPSUM, KCL trains the next generation of experts through MPhil/PhD programs in addictions research. Collaborations with NHS trusts and global partners amplify impact.

This work creates demand for faculty, research assistants, and lecturers in pharmacology. UK universities like UCL and LSHTM contribute animal modeling and epidemiology expertise. For those eyeing academic careers, AcademicJobs.com/lecturer-jobs lists openings, while postdoc positions abound in public health.

Funding from bodies like the Advisory Council on the Misuse of Drugs supports Dr. Copeland's team, positioning universities as key stakeholders in national resilience against emerging threats.

Photo by Harman Tatla on Unsplash

Towards a Safer Future: Innovations and Actionable Steps

Future outlook hinges on translating KCL's findings into practice: developing stable detection assays, real-time postmortem protocols, and education campaigns. Pilots for naloxone emergency boxes in high-risk areas show promise.

Stakeholders—from Local Government Association to charities—advocate integrated responses. For higher ed professionals, this crisis opens doors in interdisciplinary fields; explore AcademicJobs.com/uk for region-specific roles or higher-ed-jobs.

By prioritizing evidence from institutions like KCL, the UK can mitigate nitazenes' toll, saving lives through science.